Gut dysfunction and the presence of lipopolysaccharide (LPS) endotoxins contribute to the pathogenesis of Parkinson's disease (PD), leading to neuroinflammation and neurodegeneration. Modulating the gut microbiome and reducing LPS levels may hold potential as treatment strategies for PD.